MedTrace Logo

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

NCT02625168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-12-09

No results posted yet for this study

Summary

The investigators prospectively evaluated in this study the efficacy and safety profiles of afatinib as 3rd or 4th line treatment after prior failure to systemic chemotherapy and first-generation EGFR-TKI under a Boehringer Ingelheim sponsored Compassionate Use Program (CUP), with comparison of our historical cohort who received erlotinib after previous failure to systemic chemotherapy and first-generation EGFR-TKI.

Conditions

Interventions

DRUG

Afatinib

Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

DRUG

Erlotinib

Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Victor Lee, MD · Department of Clinical Oncology, The University of Hong Kong

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-09-30
Completion
2014-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02625168 on ClinicalTrials.gov